Skip to main content
SpringerLink
Log in

More than one-third of heart transplant recipients receiving sirolimus or everolimus discontinue treatment due to adverse events,

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Gonzalez-Costello J, Kaplinsky E, Manito N, Roca J, Nebot M, Barbosa MJ, Manas P, Salazar J, Miralles A, Cequier A.High Rate of Discontinuation of a Mammalian Target of Rapamycin Inhibitor Based Regime during Long-Term Follow-Up of Cardiac Transplant Recipients. 32nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation: abstr. 650, 18 Apr 2012. Available from: URL: http://www.abstracts2view.com/ishlt/view.php?nu=ishlt12l1%5f650

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

More than one-third of heart transplant recipients receiving sirolimus or everolimus discontinue treatment due to adverse events,. React. Wkly. 1403, 5 (2012). https://doi.org/10.2165/00128415-201214030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214030-00007

Keywords

Search

Navigation